Portal de Periódicos da CAPES

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders

2008; Wiley; Volume: 143; Issue: 3 Linguagem: Inglês

10.1111/j.1365-2141.2008.07355.x

1365-2141

Jennifer R. Brown, Donna Neuberg, Kimberly Phillips, Hazel Reynolds, Jason Silverstein, Jennifer C. Clark, Megan Ash, Christina Thompson, David C. Fisher, Eric D. Jacobsen, Ann S. LaCasce, Arnold S. Freedman,

Viral-associated cancers and disorders

Increasing evidence points to a heritable contribution in the development of lymphoma. The goal of this study was to determine the rate of familial lymphoproliferative malignancy among consecutive lymphoma patients presenting to a tertiary care center and to enroll families with multiple affected first-degree relatives on a data and tissue collection study. Beginning in 2004 all new patients presenting to the Dana-Farber Cancer Institute with non-Hodgkin (NHL) or Hodgkin lymphoma (HL) or chronic lymphocytic leukaemia (CLL) were asked to complete a one-page self-administered family history questionnaire. 55.4% of 1948 evaluable patients reported a first-degree relative with a malignancy, with the highest rate among CLL probands. Lymphoid malignancies were particularly common, with 9.4% of all probands reporting a first-degree relative with a related lymphoproliferative disorder (LPD). This frequency was again highest for CLL, at 13.3% of CLL probands, compared to 8.8% of NHL probands and 5.9% of HL probands (P = 0.002). The prevalence of CLL was significantly increased in parents of CLL probands (P < 0.05), and a greater risk of NHL was seen in fathers of NHL probands than in mothers (P = 0.026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden.